COMMUNIQUÉS West-GlobeNewswire

Flare Therapeutics Appoints Stephen L. Eck, M.D., Ph.D., as Chief Medical Officer
09/01/2026
CAMBRIDGE, Mass., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other [...]
Peer-reviewed study demonstrates LEON’s FR-JET® modular mixer enables stable high-concentration mRNA-LNPs with enhanced in vivo activity
09/01/2026
PLANEGG, Germany and MUNICH, Jan. 09, 2026 (GLOBE NEWSWIRE) -- A new study published in Pharmaceutics ( https://doi.org/10.3390/pharmaceutics18010050 ) shows that LEON’s FR-JET ® modular mixer addresses key [...]
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones
09/01/2026
-- Q4 2025 preliminary net product revenues from global sales of IMCIVREE ® (setmelanotide) of approximately $57 million for the fourth quarter of 2025, an 11% increase over Q3 2025 -- -- FY 2025 preliminary net product [...]
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies
09/01/2026
Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in March 2026; pending [...]
Tecan to present at upcoming Investor Conferences
09/01/2026
Männedorf, Switzerland, January 9, 2026 – The Tecan Group (SIX Swiss Exchange: TECN) today announced that it will attend and present at the following investor conferences in the upcoming week: 44 th Annual J.P. Morgan [...]
Bruder Consulting & Venture Group to become Dark Horse Consulting Regenerative Medicine
09/01/2026
WALNUT CREEK, Calif. and NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, is pleased to announce the [...]
uniQure Announces Type A Meeting Scheduled with FDA
09/01/2026
LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced a [...]
Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference
09/01/2026
MALVERN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri [...]
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026
09/01/2026
SAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and [...]
Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business Update
09/01/2026
Announces receipt of FDA letter stating it has identified deficiencies that preclude labeling discussions for Anaphylm at this time Receives confirmation from FDA that Agency’s review of Anaphylm NDA application is [...]
Sanuwave Health Announces Preliminary Q4 2025 Revenue of $13.3–$13.4 Million, Up 29–30% Year-over-Year; Achieves Record Quarterly and Full-Year Revenue
09/01/2026
Sanuwave is pleased to announce preliminary revenues of $13.3 million to $13.4 million for the fourth quarter ended December 31, 2025. This represents the highest quarterly revenues in Company history. Q4 2025 revenue [...]
Dogecoin Cash, Inc. Becomes Among the First U.S. Public Companies to Complete a FINRA‑Notified Blockchain‑Linked Security Distribution
09/01/2026
FINRA Daily List Confirms “ Dividend Payable in Another Security” for DOGP MESQUITE, NV, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Mesquite, NV January 9, 2026 — Dogecoin Cash, Inc. (OTC: DOGP) today announced that the [...]
Now Available: 1G Live Resin THCA Disposable By The Hemp Doctor
09/01/2026
MOORESVILLE, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Trusted by customers for high-quality hemp-derived THC products and vapes since 2018, The Hemp Doctor launches its newest innovation: the ZOOTED | THCA Live Resin 1G [...]
O3R-5671 Pharmacokinetic and Pharmacodynamic Data to be Presented at ECCO and Dosing in Final Cohort in First-in-human study initiated
09/01/2026
Data from the first in human study on O3R-5671’s potent TNFα inhibition to be presented Dosing of the final cohort in the first in human study has been initiated Studies in ulcerative colitis and psoriasis to initiate [...]
Allegro to start production of osteoarthritis hydrogel as it prepares for clinical trials
09/01/2026
Wallonia Minister of Economy and Employment Pierre-Yves Jeholet will perform opening ceremony on 9 January 2026 New cleanroom facility allows production of one million doses per year Ramping up for clinical development [...]
Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy
09/01/2026
Press release – No. 2 / 2026 Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy Access to Gefion, Denmark’s flagship AI [...]
Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference
09/01/2026
Saint Herblain (France), January 09, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that members of its management team will meet one-on-one with existing [...]
Valneva rencontrera des investisseurs lors de la J.P. Morgan Healthcare Conference
09/01/2026
Saint Herblain (France), le 9 janvier 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui que des membres de son équipe dirigeante rencontreront les [...]
Tecan reports return to sales growth and strong order entry in the second half of 2025
09/01/2026
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan reports return to sales growth and strong order entry in the second half of 2025 Group sales of CHF 882.5 million, down 1.6% [...]

Pages